Physician profile
Anil E Paul
NPI 1700828514
$9,478.40
in general payments reported to CMS, 2019-2025
32 companies · $2,904 in 2025
The $2,904 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $159 · 2021: $419 · 2022: $412 · 2023: $1,929 · 2024: $2,682 · 2025: $2,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,489 · Education: $26.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,488.57 |
| Education | $26.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,373.82 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,081.87 | 2021-2025 | |
| Novo Nordisk INC | $896.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $826.31 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $746.70 | 2019-2025 | |
| Pfizer INC. | $623.16 | 2019-2025 | |
| Amgen INC. | $533.18 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $480.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $420.82 | 2023-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $320.18 | 2019-2024 | Spravato, Xarelto |
| Esperion Therapeutics, INC. | $300.08 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $237.94 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $227.81 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $222.88 | 2024-2025 | Voquezna |
| Abbott Laboratories | $148.68 | 2022-2025 | Freestyle Libre 2 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $139.10 | 2021-2025 | Watchman Access System |
| Teleflex LLC | $115.95 | 2025 | Urolift |
| Medtronic, INC. | $107.03 | 2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $99.24 | 2019-2024 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.40 | 2023-2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $81.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.28 | 2023-2024 | Ofev, Jardiance |
| Dexcom, INC. | $65.25 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $64.17 | 2019 | |
| Xeris Pharmaceuticals, INC. | $58.36 | 2025 | Recorlev, Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $29.99 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $27.44 | 2023 | Livalo |
| Merck Sharp & Dohme LLC | $19.21 | 2023 | Pneumovax 23, Vaxneuvance, M-M-R II |
| Ultragenyx Pharmaceutical INC. | $16.85 | 2024 | Crysvita |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.04 | 2024 | Rayaldee |
| Aimmune Therapeutics, INC. | $14.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.